Corporate Presentation
Obesity
Survodutide
Treatment with survodutide in the Phase 2 obesity trial
showed no unexpected safety findings
As expected, Gl disorders were the most frequent drug-related AEs
ZBAL&
ZEALAND PHARMA
Boehringer
Ingelheim
• Most treatment discontinuations occurred during the rapid dose escalation phase (up to Week 20) and may be mitigated with
more gradual dose-escalation
TEAE, n (%) a
Survodutide
0.6 mg (n=77)
Survodutide
2.4 mg (n=78)
Survodutide
3.6 mg (n=77)
Survodutide
4.8 mg (n=77)
Survodutide
total (n=309)
Placebo
(n=77)
Any TEAE
Nauseab
70 (90.9)
70 (89.7)
71 (92.2)
70 (90.9)
281 (90.9)
58 (75.3)
26 (33.8)
51 (65.4)
48 (62.3)
49 (63.6)
174 (56.3)
15 (19.5)
Vomitingb
7 (9.1)
23 (29.5)
26 (33.8)
27 (35.1)
83 (26.9)
4 (5.2)
Diarrheab
14 (18.2)
22 (28.2)
18 (23.4)
15 (19.5)
69 (22.3)
8 (10.4)
Constipationb
9 (11.7)
17 (21.8)
19 (24.7)
20 (26.0)
65 (21.0)
4 (5.2)
Leading to treatment
15 (19.5)
20 (25.6)
19 (24.7)
22 (28.6)
76 (24.6)
3 (3.9)
discontinuation
Gl-related
5 (6.5)
13 (16.7)
13 (16.9)
20 (26.0)
51 (16.5)
1 (1.3)
Serious
1 (1.3)
2 (2.6)
6 (7.8)
Investigator defined,
47 (61.0)
66 (84.6)
62 (80.5)
4 (5.2)
62 (80.5)
13 (4.2)
5 (6.5)
237 (76.7)
29 (37.7)
drug-related TEAE
Serious, drug-related TEAE
0 (0.0)
0 (0.0)
2 (2.6)
0 (0.0)
2 (0.6)
0 (0.0)
aBased on the treated set and presented according to planned treatment; "TEAEs listed according to preferred term and occurred in ≥15% patients in any treatment arm.
Survodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for development and commercialization globally (subject to Zealand's co-promotion rights in the Nordic countries).
Source: Table adapted from Le Roux et al. Oral presentation (51-OR) at ADA 83rd Scientific Sessions, San Diego, June 23-26, 2023.
AE=adverse event; Gl=gastrointestinal; TEAE-treatment-emergent adverse event.
27View entire presentation